Structural Bioinformatics Software Global Market Report 2026

The structural bioinformatics software market size has grown rapidly in recent years. It will grow from $1.56 billion in 2025 to $1.71 billion in 2026 at a compound annual growth rate (CAGR) of 10.1%. The growth in the historic period can be attributed to increasing demand for protein structure analysis, growth of pharmaceutical and biotechnology research, adoption of molecular modeling tools, rising focus on genomics and proteomics studies, development of visualization and analysis software.

The structural bioinformatics software market size is expected to see rapid growth in the next few years. It will grow to $2.54 billion in 2030 at a compound annual growth rate (CAGR) of 10.3%. The growth in the forecast period can be attributed to ai-powered structural prediction adoption, cloud deployment of bioinformatics platforms, integration with advanced drug discovery workflows, expansion of academic and research institute capabilities, demand for high-throughput and collaborative analysis solutions. Major trends in the forecast period include ai-driven structural predictions, cloud-based structural bioinformatics platforms, high-throughput molecular simulations, integration with drug discovery pipelines, collaborative structural data management.

The increasing adoption of personalized medicine is expected to drive the expansion of the structural bioinformatics software market in the coming years. Personalized medicine is a method that tailors healthcare and treatments based on an individual patient’s unique biological and personal characteristics. Its adoption is growing due to advancements in genomic technologies, which enable healthcare providers to rapidly and accurately analyze a patient’s genetic information, allowing for more precise and effective therapies. Structural bioinformatics software supports personalized medicine by analyzing the 3D structures of proteins and other biomolecules to predict how individual genetic variations influence drug response, enabling customized therapies for each patient. For instance, in February 2024, according to the Personalized Medicine Coalition, a US-based non-profit organization, the FDA approved 16 new personalized treatments for rare disease patients in 2023, compared to six in 2022. The newly approved treatments for 2023 also included seven cancer drugs and three for other diseases and conditions. Therefore, the growing use of personalized medicine is driving growth in the structural bioinformatics software market.

Leading companies operating in the structural bioinformatics software market are focusing on developing innovative solutions, such as integrated structural biology computational platforms, to accelerate drug discovery, optimize protein engineering, and enhance molecular modeling accuracy. Integrated structural biology computational platforms are advanced digital systems that combine modeling, simulation, and data analysis tools to study the three-dimensional structure of biological molecules that help researchers understand molecular interactions, predict protein structures, and accelerate drug discovery and life science research. For example, in August 2025, Biortus, a US-based contract research organization, launched BiortusAI, an AI- or ML-powered integrated structural biology computational platform that accelerates protein design, antibody engineering, and hit discovery. The platform integrates structural biology data from X-ray crystallography and cryo-EM with advanced models like AlphaFold2, Chai-1/2, and Proteinix, enabling workflows for enzyme optimization, nanobody design, and rapid GPCR hit identification with high accuracy. This structural bioinformatics tool shortens drug discovery cycles by over 50% through AI-driven virtual screening and high-performance computing.

In August 2023, Optibrium Ltd., a UK-based software company, acquired BioPharmics LLC for an undisclosed sum. Through this acquisition, Optibrium seeks to enhance its 3D drug design and visualization capabilities by incorporating BioPharmics’ advanced molecular modeling and visualization technologies, enabling researchers to more effectively design and optimize novel therapeutics. BioPharmics LLC is a US-based biotechnology company focused on delivering 3D ligand- and structure-based modeling software used in computational drug design.

Major companies operating in the structural bioinformatics software market are Dassault Systèmes SE, Schrödinger Inc., DeepMind Limited, Simulations Plus Inc., Chemical Computing Group ULC, MolSoft LLC, Cresset Group Ltd., OpenEye Scientific Software Inc., Nimbus Therapeutics LLC, Optibrium Ltd., DNASTAR Inc., Bioinformatics Solutions Inc., BioSolveIT GmbH, Acellera Ltd., InteLigand GmbH, Alchemistry Ltd., OpenStructure, Insilico Medicine Ltd., Exscientia plc, and Biortus Biosciences Co. Ltd.

North America was the largest region in the structural bioinformatics software market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the structural bioinformatics software market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the structural bioinformatics software market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The structural bioinformatics software market consists of revenues earned by entities by providing services such as protein structure prediction, molecular visualization, and molecular docking. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Structural bioinformatics software is a set of computational tools used to analyze, visualize, and predict the three-dimensional structures of biological macromolecules, including proteins and nucleic acids. These platforms facilitate understanding of molecular functions, interactions, and dynamics, supporting applications in drug design, protein engineering, and molecular simulations.

The key product types of structural bioinformatics software include visualization software, modeling software, analysis software, database management software, and other variants. Visualization software provides graphical representations of molecular structures. Solutions are deployed through on-premises and cloud-based models. Applications include drug discovery, protein structure analysis, molecular dynamics, genomics, and proteomics, serving pharmaceutical and biotechnology companies, academic and research institutes, contract research organizations, and other end users.

Tariffs have affected the structural bioinformatics software market by increasing the cost of importing high-end visualization, modeling, and analysis software, as well as database management tools. Segments such as modeling and analysis software are particularly impacted in regions like North America and Europe where reliance on imported solutions is high. Despite these challenges, tariffs are encouraging local software development, investment in domestic platforms, and innovation in cost-efficient solutions, which may strengthen market resilience and promote regional adoption.

The structural bioinformatics software market research report is one of a series of new reports that provides structural bioinformatics software market statistics, including structural bioinformatics software industry global market size, regional shares, competitors with a structural bioinformatics software market share, detailed structural bioinformatics software market segments, market trends and opportunities, and any further data you may need to thrive in the structural bioinformatics software industry. This structural bioinformatics software market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

This product will be delivered within 1-3 business days.